Fount Bio Awarded Prestigious Innovation of the Year at 2024 IMCAS

Fount Bio wins first prize at the Innovation Tank competition for its development of the world’s first platform of products that build crosslinked hyaluronic acid within living tissues

CAMBRIDGE, MA  February 12, 2024 – Life sciences innovator Fount Bio, Inc., won first place in the Innovation Tank event at the IMCAS World Congress 2024 in Paris. In this highly competitive and coveted event, Fount Bio was invited to present its Flī-Derm™ aesthetic dermatology product on February 2, winning the Innovation of the Year award.

IMCAS is the world’s largest conference dedicated to aesthetic medicine and aging science. This year’s event was attended by 18,000 participants from around the world including innovators, physicians, and representatives from industry and finance. The Innovation Tank competition, which was styled after the Shark Tank television show, allowed select participants to present their innovations, followed by a question-and-answer period by a 10-member jury of senior opinion leaders from medicine, industry, and finance.

Based on Fount Bio’s proprietary Flī-HA™ bioorthogonal chemistry platform, the Flī-Derm™ product enables the building of durable forms of hyaluronic acid (HA) within the dermis via a liquid formulation that is delivered with a gentle form of assisted delivery. In a blinded clinical study, Flī-Derm™ was shown to significantly reduce fine lines and wrinkles relative to control treatment, while demonstrating exceptional safety and tolerability.

“We are thrilled to be recognized as the Innovation of the Year by IMCAS’ Innovation Tank. This is strong validation of the exciting potential of our Flī-Derm™ product and the power of our Fli-HA™ technology platform,” said Fount Bio co-founder and CEO Doug Levinson, Ph.D. “We look forward to advancing our product towards commercial launch and providing the medical aesthetics community with exciting new possibilities for improving the health and well-being of patients.”

Fount Bio’s Flī-HA technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. In addition to Flī-Derm™, Fount Bio has a pipeline of medical products in development for ophthalmology and women’s health.

About Fount Bio

Fount Bio is a life science company developing a pipeline of innovative products for medical   applications based on proprietary technology that combines innovations in biorthogonal chemistry and glycopolymer science. Led by an experienced management team and highly respected scientific advisors, Fount Bio combines scientific excellence, a pioneering spirit, and extensive experience in building high-value life sciences companies. The company is headquartered in Cambridge, Massachusetts, USA. Learn more at fountbio.com

Please direct press inquiries to info@fountbio.com or +1 (617) 249-3552

fountbio

Fount Bio selected to present its Flī-Derm™dermatology product at IMCAS

Company will present its innovative aesthetic dermatology product
in the Innovation Tank at IMCAS in Paris, February 2, 2024

CAMBRIDGE, MA  January 24, 2024 – Life sciences innovator Fount Bio, Inc., today announced it has been selected to participate in the Innovation Tank event at the IMCAS World Congress 2024, presenting its Flī-Derm™ aesthetic dermatology product. The Innovation Tank invites a select set of companies that are developing promising, new dermatology innovations the opportunity to showcase their solutions and compete for the Innovation of the Year award.

Based on Fount Bio’s proprietary Flī-HA™ bioorthogonal chemistry platform, the Flī-Derm™ product enables the building of durable forms of hyaluronic acid (HA) within the dermis via a liquid formulation that is delivered through skin micro-perforation. In a blinded clinical study, Flī-Derm™ was shown to reduce fine lines and wrinkles relative to control treatment, while demonstrating exceptional safety and tolerability.

“We are very excited to be among the select few innovators invited to participate in this premier international event for dermatology innovators,” said Fount Bio co-founder and CEO Doug Levinson, Ph.D., noting the competitive Innovation Tank selection process. “We look forward to presenting the Flī-Derm™ product, innovative Fli-HA™ technology and our product vision to the broader medical aesthetics community. Our innovation offers exciting possibilities for improving the health and well-being of patients.”

Fount Bio’s Flī-HA technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. In addition to Flī-Derm™, Fount Bio is developing a pipeline of products medical applications in the fields of  ophthalmology and gynecology.

About Fount Bio

Fount Bio is a life science company developing a pipeline of innovative products for medical   applications based on proprietary technology that combines innovations in biorthogonal chemistry and glycopolymer science. Led by an experienced management team and highly respected scientific advisors, Fount Bio combines scientific excellence, a pioneering spirit, and extensive experience in building high-value life sciences companies. The company is headquartered in Cambridge, Massachusetts, USA. Learn more at fountbio.com

Please direct press inquiries to info@fountbio.com or +1 (617) 249-3552

Fount Bio’s Flī-Derm™ dermatology product demonstrates impressive aesthetic improvement in clinical study

The company will present results of its blinded study at the Dermatology Summit at JPM 2024 in San Francisco on January 7, 2024

CAMBRIDGE, MA December 11, 2023 – Life sciences innovator Fount Bio, Inc., today announced it has successfully completed its first clinical study demonstrating the safety and efficacy of its novel product for aesthetic dermatology. The product, Flī-Derm™, is based on the company’s proprietary Flī-HA bioorthogonal chemistry platform that enables the building of durable forms of hyaluronic acid (HA) on or within tissues via microneedling. Results of the study will be presented at the Dermatology Summit at the JPM Healthcare Conference in San Francisco on January 7, 2024.

The study, designed with blinded physician assessments, clearly demonstrates aesthetic improvement, including reducing fine lines and wrinkles, relative to control treatment. It also demonstrated exceptional safety and tolerability.

“These study results confirm the ability of our bioorthogonal chemistry platform to overcome key challenges associated with the delivery of hyaluronic acid,” said Fount Bio co-founder and CEO Doug Levinson, Ph.D. “As the lead product using our proprietary technology, Flī-Derm offers exciting possibilities for improving the health and well-being of patients. We look forward to presenting our study results with the clinical dermatology community at JPM 2024.”

Dr. Jeff Dover, M.D., one of Fount Bio’s clinical advisors, commented, “These encouraging clinical results support Flī-Derm’s potential to become an exciting new treatment option for patients and consumers seeking long-lasting improvement in skin quality. The high-tolerability profile and simplified, injectionless procedure should be very appealing to both patients and their providers.”

Fount Bio’s Flī-HA technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. In addition to Fli-Derm, Fount Bio has pipeline efforts in ophthalmology and gynecology.

About Fount Bio

Fount Bio is a life science company developing a pipeline of innovative products for medical and beauty applications based on proprietary technology that combines innovations in biorthogonal chemistry and glycopolymer science. Led by an experienced management team and highly respected scientific advisors, Fount Bio combines scientific excellence, a pioneering spirit, and extensive experience in building high-value life sciences companies. The company is headquartered in Cambridge, Massachusetts, USA. Learn more at fountbio.com.

Please direct press inquiries to info@fountbio.com or +1 ‪(617) 249-3552‬‬‬‬‬‬‬‬‬‬‬.

Page Banner

a:7:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:4:”page”;}}}s:8:”position”;s:6:”normal”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;}

Popups

a:8:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:4:”page”;}}}s:8:”position”;s:6:”normal”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;s:12:”show_in_rest”;b:0;}

Fount Bio announces Dan Browne, MBA to join Board of Directors.

Fount Bio, Inc. is pleased to announce the appointment of Dan Browne as an independent Director to Fount Bio’s Board of Directors. Dan joins current board members Anthony Aiudi and Justin Burns from Morningside Ventures and co-founders Samir Mitragotri and Douglas Levinson.

Dan Browne has more than 30 years of entrepreneurial and executive leadership experience in the healthcare industry. He has led the development of multiple innovative products that are leaders in their category, as well as critical business development and partnership activities. Dan is the co-founder and former CEO of Revance Therapeutics, Inc. He brought the company from early-stage incubator in 2002 to a highly successful IPO in 2014. During Dan’s tenure at Revance, all the core R&D, clinical, regulatory/quality, finance and commercial operations reported to him.

“We are honored to have Dan join our Board. Dan brings outstanding knowledge and experience to Fount Bio and will strengthen our efforts to translate our Flī-HA (functional ligand hyaluronic acid) platform technology for topical delivery of hyaluronic acid (HA) into exciting, category leading products.” said Douglas Levinson, Founder and CEO, Fount Bio. “Dan’s expertise in bringing early-stage innovation all the way through the necessary steps to commercial readiness and successful IPO will be extraordinarily valuable as we grow Fount Bio.”

“I am excited about the opportunity that Fount Bio and the Flī-HA platform represent. There is significant unmet need for a novel, tailored and targeted topical delivery mechanism for hyaluronic acid.” said Dan Browne. “The robust scientific expertise, data generated to date and the pedigree of the Fount Bio leadership team gives me confidence in what they have and the potential breakthrough in the delivery of hyaluronic acid. I am looking forward to supporting them on that journey.”  

Fount Bio is currently developing its novel and proprietary Flī-HA for aesthetics and dermatological use while also exploring product opportunities across a range of high potential market categories where Flī-HA provides important and distinct advantages. Currently, marketed HA-based products encompass a broad range of high-value commercial opportunities. In the medical aesthetics area alone, the current market for HA injectables is expected to approach $6B by 2025. Flī-HA-based products have the potential to grow and capture market share even further by providing a topical alternative to injection.

About Flī-HA, the first of its kind technology

Fount Bio’s proprietary Flī-HA (functional ligand-hyaluronic acid) platform is the world’s first platform designed to build a biostable HA matrix where it’s needed. It’s based on natural biochemical reactions that occur within living systems. As a result, Flī-HA technology overcomes longstanding delivery and biostability challenges of large glycoproteins like HA and enables HA to be topically delivered either on tissue surfaces or deeper, where it’s retained for extended periods.

About Fount Bio

Fount Bio is a life science company developing a pipeline of innovative products for medical and beauty applications based on proprietary glycopolymer technology that combines proprietary innovations in biorthogonal chemistry and glycopolymer science. Fount Bio’s Flī- technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. Our Flī-HA platform technology delivers hyaluronic acid, a naturally occurring and necessary component present in various tissues throughout the body, including skin, eyes, joints and mucosa. For more information, visit www.fountbio.com

Fount Bio closes Series A financing led by Morningside Ventures to advance Flī-HA platform technology to clinical proof of concept.

Fount Bio, Inc. successfully closed a Series A round of financing led by Morningside Ventures. This initial investment will be focused on progressing Fount Bio’s, Flī-HA (functional ligand hyaluronic acid) technology forward into clinical evaluation for aesthetic and dermatological indications. Anthony Aiudi and Justin Burns from Morningside Ventures will be joining founders Samir Mitragotri and Doug Levinson on Fount’s Board of Directors.

“We are thrilled to come in at this early stage and support development of Fount Bio’s Flī-HA platform technology and their lead product concept. Our focus is on supporting compelling and novel innovations that have the potential to change the category or treatment paradigm. We have a strong track record of breakthrough and FastTrack programs under our belt and we feel that the innovation being developed by Fount Bio in Flī-HA has the potential to follow suit.”  Anthony Aiudi, Morningside Ventures.

Hyaluronic Acid (HA), is a naturally occurring component that serves a key role in various tissues throughout the body, including skin, eyes, joints and mucosa. Topical delivery of HA into tissues like skin has been long sought after but has not been possible to date given the large size of HA. Flī-HA technology overcomes longstanding delivery and biostability challenges associated with large HA glycopolymers and enables them to be topically delivered – either onto tissue surfaces or deeper within tissues – and with long duration retention.

“I am extremely excited about our partnership with Morningside Ventures and their longstanding commitment to supporting and advancing development of novel high-impact products based on breakthrough technologies. The Morningside team brings tremendous value to Fount Bio and enables us to translate our proprietary hyaluronic acid (HA) Flī-HA platform technology into exciting and innovative new products. The unmet need for targeted, topical HA delivery presents a real opportunity and we hope to demonstrate the potential in aesthetics and dermatology as well as future categories as we further the development of Flī-HA” – Douglas Levinson, Fount Bio Founder and CEO

Fount Bio’s initial focus is to develop Flī-HA-based products for the aesthetics, medical dermatology, and consumer beauty markets. In the medical aesthetics area alone, HA-based injectable products generate sales approaching $6B annually.

Beyond the initial focus on aesthetic and medical dermatology applications, Fount Bio is exploring development of products across a range of high potential market categories where  Flī-HA can provide important and distinct advantages.    

About Morningside Ventures

Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com

About Fount Bio

Fount Bio is a life science company developing a pipeline of innovative products for medical and beauty applications based on proprietary biopolymer technology that combines proprietary innovations in biorthogonal chemistry and biopolymer science. Fount Bio’s Flī- technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. Our Flī-HA platform technology delivers Hyaluronic Acid (HA), a naturally occurring and necessary component present in various tissues throughout the body, including skin, eyes, joints and mucosa. For more information visit www.fountbio.com